In a prospective, double-blinded, placebo-controlled RCT of EMPA in NAFLD patients without T2DM, 24 weeks of EMPA treatment notably decreased serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and liver fat content as compared to baseline [14]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.